Monitor the EADV and FCD conferences for actual data readouts from the ATTO-1310 Phase 1b interim results, which could provide early efficacy signals in atopic dermatitis and chronic pruritus. No immediate stock-moving catalyst.
Price Chart
Executive Summary
Attovia Therapeutics announced it will present new clinical, translational, and preclinical data across its pipeline at the EADV 2026 and FCD 2026 conferences. The presentations include Phase 1a healthy volunteer data, interim Phase 1b data for ATTO-1310 in atopic dermatitis and chronic pruritus, and preclinical data for ATTO-2306. This is a routine pipeline update with no new binary catalyst or material financial data.
Key Facts
- Attovia will present four posters at EADV 2026 (Sept 30-Oct 3) and FCD 2026 (Oct 8-11).
- Three posters cover ATTO-1310 (anti-IL-31 ATTOBODY): Phase 1a healthy volunteer data, translational IL-31 data, and interim Phase 1b data in high-itch atopic dermatitis or chronic pruritus.
- One poster covers ATTO-2306 (anti-IL-31/IL-13 bispecific): new preclinical data.
- No efficacy or safety results were disclosed in the press release.
Financial Impact
No financial data disclosed.
Risk Factors
- Phase 1b interim data may show insufficient efficacy or safety issues.
- No disclosed financial runway or cash position; early-stage biotech with no approved products.
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3370251 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 8, 2026 18d ago | 3/A | $16.21 | awaiting T+20 | — | $13.88 (−14.37%) |
Oct 8, 2026 18d ago | 3/A | $16.21 | awaiting T+20 | — | $13.88 (−14.37%) |
Sep 28, 2026 28d ago | Press Release | $18.16 | awaiting T+20 | — | $13.88 (−23.57%) |
Sep 2, 2026 7w ago | Press Release | $24.20 $17.14 | ▼ −29.17% | ▼ −28.06% | $13.88 (−42.64%) |
Aug 28, 2026 8w ago | 144 / CLUSTER | $21.40 $18.16 | ▼ −15.14% | ▼ −14.95% | $13.88 (−35.14%) |
Aug 13, 2026 10w ago | Insider Buy | $19.86 $24.52 | ▲ +23.46% | ▲ +25.46% | $13.88 (−30.11%) |
Aug 13, 2026 10w ago | Insider Cluster | $19.86 $24.52 | ▲ +23.46% | ▲ +25.46% | $13.88 (−30.11%) |
Aug 10, 2026 11w ago | Insider Cluster | $18.65 $22.86 | ▲ +22.57% | ▲ +23.63% | $13.88 (−25.58%) |
Aug 7, 2026 11w ago | Insider Cluster | $19.84 $23.66 | ▲ +19.25% | ▲ +20.17% | $13.88 (−30.04%) |
Aug 7, 2026 11w ago | Insider Cluster | $20.17 $25.55 | ▲ +26.67% | ▲ +27.07% | $13.88 (−31.18%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers